The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Georgios Tsivgoulis1,2,3*, Aristeidis H. Katsanos1,4, Nikolaos Grigoriadis5, Georgios M. Hadjigeorgiou6, Ioannis Heliopoulos7, Panagiotis Papanasopoulos8, Constantinos Kilidireas9, Konstantinos Voumourakis1, Efthimios Dardiotis6, HELANI (Hellenic Academy of Neuroimmunology)¶

1 Second Department of Neurology, “Attikon” Hospital, School of Medicine, University of Athens, Athens, Greece, 2 Department of Neurology, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America, 3 International Clinical Research Center, Department of Neurology, St. Anne’s University Hospital in Brno, Brno, Czech Republic, 4 Department of Neurology, School of Medicine, University of Ioannina, Ioannina, Greece, 5 Second Department of Neurology, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece, 6 Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, 7 Department of Neurology, Alexandroupolis University Hospital, Democritus University of Thrace, Alexandroupolis, Greece, 8 Department of Neurology, University of Patras Medical School, Patras, Greece, 9 First Department of Neurology, “Eginition” Hospital, School of Medicine, University of Athens, Athens, Greece

¶ Membership of the Hellenic Academy of Neuroimmunology is listed in the Acknowledgments.
* tsivgoulisg@yahoo.gr

Abstract

Importance
A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to systematically evaluate the effect of DMDs on disability progression in RRMS

Methods
We performed a systematic review on MEDLINE and SCOPUS databases to include all available placebo-controlled randomized clinical trials (RCTs) of RRMS patients that reported absolute numbers or percentages of disability progression during each study period. Observational studies, case series, case reports, RCTs without placebo subgroups and studies reporting the use of RRMS therapies that are not still officially approved were excluded. Risk ratios (RRs) were calculated in each study protocol to express the comparison of disability progression in RRMS patients treated with a DMD and those RRMS patients receiving placebo. The mixed-effects model was used to calculate both the pooled point estimate in each subgroup and the overall estimates.
Results
DMDs for RRMS were found to have a significantly lower risk of disability progression compared to placebo (RR = 0.72, 95%CI: 0.66–0.79; p<0.001), with no evidence of heterogeneity or publication bias. In subsequent subgroup analyses, neither dichotomization of DMDs as “first” and “second” line RRMS therapies [(RR = 0.72, 95% CI = 0.65–0.80) vs. (RR = 0.72, 95% = 0.57–0.91); p = 0.96] nor the route of administration (injectable or oral) [RR = 0.75 (95% CI = 0.64–0.87) vs. RR = 0.74 (95% CI = 0.66–0.83); p = 0.92] had a differential effect on the risk of disability progression. Either considerable (5–20%) or significant (>20%) rates of loss to follow-up were reported in many study protocols, while financial and/or other support from pharmaceutical industries with a clear conflict of interest on the study outcomes was documented in all included studies.

Conclusions
Available DMD are effective in reducing disability progression in patients with RRMS, independently of the route of administration and their classification as “first” or “second” line therapies. Attrition bias needs to be taken into account in the interpretation of these findings.

Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests with acute relapses and progressive disability [1]. Expanded Disability Status Scale (EDSS) change is the main outcome measure used in MS clinical studies [2], as a potential indicator of neurological improvement that correlates directly with the quality of patients’ life [3]. In clinical practice EDSS progression is considered one of main indicators for change in treatment for MS patients with clinical deterioration [4], as it has been observed that increases in EDSS scale are independently associated with MS therapy cessation [5].

A number of officially approved disease-modifying drugs (DMD), including novel oral agents, are currently available for the aggressive early intervention in patients with relapsing-remitting MS (RRMS), promising higher treatment goals and long-term outcomes improvement [6]. Even though DMDs are considered to be equally effective in delaying EDSS progression in RRMS patients [7], observational study data report that both DMD choice and cumulative treatment duration may have a significant impact on EDSS change in patients with RRMS [8, 9].

The aim of the present meta-analysis was to systematically investigate the effect of all available DMDs on disability progression reduction in RRMS using follow-up data from all available placebo-controlled randomized clinical trials (RCT). Moreover, we sought to evaluate potential sources of heterogeneity regarding the potential differential effect of DMD subgroups on disability progression.

Methods
Trial identification and data abstraction
This meta-analysis is presented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews and meta-analyses (S1 PRISMA Checklist) [10]. Eligible placebo-control RCTs that reported absolute numbers or
percentages of RRMS patients with disability progression during the study period were identified by searching MEDLINE, SCOPUS and the CENTRAL Register of Controlled Trials. The following keywords were used in all database searches: “relapsing-remitting multiple sclerosis”, “RRMS”, “disability” and “EDSS change”. We imposed no language or other restrictions. Last literature search was performed on February 7th, 2015. We examined reference lists of all retrieved articles to identify studies that may have been missed by the initial database search.

Database search was performed independently by three reviewers (GT, ED & AHK) to include only placebo-control RCTs that reported either the absolute or the percent numbers of RRMS patients with disability progression during the study period in both treatment and placebo subgroups. We excluded from the quantitative/qualitative analysis all: 1. Observational studies, 2. case series, 3. case reports, 4. RCTs without placebo subgroups and 5. studies reporting the use of RRMS therapies that are not still officially approved. Emerging disagreements regarding the literature search results between the three coauthors, were resolved with consensus [6].

In each eligible study we used a predefined 7-point quality control to address for biases. For each quality item the corresponding risk of bias was categorized as low, high or unclear according to the suggestions by Higgins et al [11, 12]. Complete outcome data were judged as "low risk" when the percentage of participants lost to follow-up was lower than 5% and "high risk" when the reported loss to follow up was more than 20%. In studies reporting loss to follow up between 5%-20% the risk of attrition bias was categorized as "unclear" [13]. In the “other bias” category we included all other potential sources of bias, including the source of funding reported in each protocol [11, 14]. Bias identification within studies was independently performed by the three reviewers who performed the literature search. (GT, AHK, ED). All emerging conflicts in quality control were resolved with consensus.

Absolute or percent numbers of RRMS patients with disability progression during the study period were extracted independently after bias identification by the same authors (GT, ED & AHK). The active treatment arm with the finally approved dose of DMD was selected in each trial for comparisons versus the placebo arm.

Statistical analyses

We calculated Risk ratios (RRs) in each study protocol to express the comparison of disability progression in RRMS patients treated with a DMD and those RRMS patients receiving placebo. RR values smaller than 1 denote that the treatment under investigation has a positive effect in the number of RRMS patients with disability progression compared to placebo. A random-effects model (DerSimonian Laird) was used to calculate the pooled RRs. The equivalent z test was performed for each pooled RR, and if p < 0.05 it was considered statistically significant [11].

We assessed heterogeneity between studies with the Cochran Q and I² statistics. For the qualitative interpretation of heterogeneity, I² values of at least 50% were considered to represent substantial heterogeneity, while values of at least 75% indicated considerable heterogeneity, as per the Cochrane Handbook [11, 15]. We evaluated publication bias both graphically using a funnel plot [16] and with the Egger’s statistical test for funnel plot asymmetry [17].

After the main analysis, we conducted predefined subgroup analyses according to (i) current categorization of eligible DMDs as “first line” (INFb-1b, peginterferon beta-1a, glatiramer acetate, INFb-1a, teriflunomide, dimethyl fumarate) and “second line” (natalizumab & fingolimod) RRMS treatments (ii) the DMT route of administration: injectable subcutaneously (IFNβ-1a, IFNβ-1b, peginterferon beta-1a and glatiramer acetate) or intramusculary (IFNβ-1a) vs. oral (fingolimod, teriflunomide, dimethyl fumarate).
We used the mixed-effects model was used to calculate both the pooled point estimate in each subgroup and the overall estimates [11]. According to the mixed-effects model, a random effects model was first used to combine studies within each subgroup and then a fixed effect model was used to combine subgroups and estimate the overall effect. We assumed the study-to-study variance (tau-squared) to be the same for all subgroups. Tau-squared was first computed within subgroups and then pooled across subgroups [11].

Finally, we performed univariate post-hoc meta-regression analyses, using the random effects model (Method of Moments), to evaluate reported study duration as a possible moderator of the percentage of patients with disability progression.

Statistical analyses were conducted using Review Manager (RevMan) Version 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Comprehensive Meta-analysis Version 2 software (Borenstein M, Hedges L, Higgins J, Rothstein H, Biostat, Englewood NJ, 2005).

Results

Study selection and study characteristics

Database search of MEDLINE and SCOPUS yielded 266 and 247 results respectively. No additional RCTs were identified in the CENTRAL Register of Controlled Trials database. After removing duplicate studies, the titles and abstracts from the remaining 477 studies were screened and 17 potentially eligible studies for the meta-analysis were retained. After retrieving the full-text version of the aforementioned 17 studies, 4 studies were excluded because they provided neither percentages nor numbers of patients with disability progression during the study period [18–21]. No disagreement about the literature search results emerged between the three reviewers and the 13 studies that met the predefined inclusion/exclusion criteria were included both in the qualitative and quantitative synthesis (Fig 1) [22–34]. The characteristics of the included studies (9788 total RRMS patients) are summarized in S1 Table. The following treatment arms (including only placebo arms and active arms with approved doses of available DMD) of the 13 selected RCT were included in the present analyses: INFβ-MS (INFβ-1b 0.25mg/ml subcutaneous) [22], Copolymer (glatiramer acetate 20mg/ml subcutaneous) [23], MSCRG (INFβ-1a 30mcg/ml intramuscular) [24], PRISMS (INFβ-1a 22mcg/0.5ml or 44mcg/0.5ml subcutaneous) [25], AFFIRM (natalizumab 20mg/ml intravenous) [26], FREEDOMS I (fingolimod 0.5mg/cap per os) [27], FREEDOMS II (fingolimod 0.5mg/cap per os) [28], TEMSO (teriflunomide 14mg/tab per os) [29], TOWER (teriflunomide 14mg/tab per os) [30], CONFIRM (dimethyl fumarate 240mg/cap) [31], DEFINE (dimethyl fumarate 240mg/cap) [32], GALA (glatiramer acetate 40mg/ml subcutaneous) [33], ADVANCE (peginterferon beta-1a 125 μg/ml subcutaneously) [34]. The duration of studies varied from 1 year to 3 years. One year follow-up was reported in 5 study protocols [23, 27, 28, 33, 34], approximately 1.5 year follow-up in one study protocol [30], two year follow-up in 4 studies [24, 20, 31, 32], approximately 2.5 years in one study [26] and three year follow-up in two studies [22, 29]. In all studies, except for one [24], disability progression was assessed at 3-months.

Risk of bias for independent studies

Risk of bias in the included studies is summarized in Fig 2A and 2B. Random sequence generation and allocation concealment was adequately reported in all trials, except for two [22, 23]. Blinding of participants, personnel and outcome assessment was sufficient in all protocols. Six of the study protocols reported loss to follow up percentages between 5%-20% [22–27], 5 studies reported loss to follow up more than 20% of the baseline number of participants [28–32] and the remaining 2 studies reported losses to follow-up less than 5% [33, 34]. Selective
reporting bias was detected in only one study [26]. All study protocols were supported financially partly [23, 24] or solely [25–32, 33, 34] by the pharmaceutical companies that produce and market the drug under consideration in each study. Funding sources were not reported in the disclosures of one study protocol [22], providing thus insufficient information to permit judgment.

Overall analysis and subgroup analyses

Patients receiving approved DMDs for RRMS were found to have a significantly lower risk of disability progression compared to those receiving placebo (RR = 0.72, 95%CI: 0.66–0.79; p<0.001; Fig 3). No evidence of heterogeneity was found between estimates (I² = 6%, p = 0.39). Moreover, no evidence of publication bias was detected in the funnel plot inspection (S1 Fig) or in the Egger’s statistical test (p = 0.178).
Fig 2. A) Risk of bias summary. Review authors' judgments about each risk of bias item for each included study. B) Risk of bias graph. Review authors' judgments about each risk of bias item presented as percentages across all included studies.

doi:10.1371/journal.pone.0144538.g002
In subsequent subgroup analyses, neither dichotomization of DMTs as “first” and “second” line RRMS therapies [RR = 0.72 (95% CI = 0.65–0.80) vs. RR = 0.72 (95% CI = 0.57–0.91); p = 0.96; Fig 4] nor the route of administration (injectable or oral) [RR = 0.75 (95% CI = 0.64–0.87) vs. RR = 0.74 (95% CI = 0.66–0.83); p = 0.92; Fig 5] had a differential effect on the risk of disability progression throughout each study follow-up period. In both the aforementioned analyses no evidence of substantial heterogeneity was found both within and between subgroups (p > 0.05 for Cochran Q test & I² < 75%).

In meta-regression analysis, the percentage of patients with disability progression was not found to be associated with the reported study duration (regression slope = -0.14; 95% CI: -0.39–0.11; p = 0.263; S2 Fig).

**Discussion**

Our study showed that currently approved DMD for RRMS are effective in reducing disability progression compared to placebo. In all study protocols, except for two [24, 33], disability progression was assessed at 3-months and this is one of the main strengths of pooling EDSS data across trials. Moreover, we detected no significant heterogeneity in the risk reduction of disability progression across different subgroup analyses including “first” vs. “second” line DMD and oral vs. injectable route of administration.

In the pairwise comparison of a recent network meta-analysis on the currently available immunomodulator and immunosuppressive treatments for multiple sclerosis natalizumab and subcutaneous IFNβ-1a were found to be significantly more effective (OR = 0.62, 95% CI:0.49–0.78 and OR = 0.35, 95% CI:0.17–0.70, respectively) than intramuscular IFNβ-1a in the reduction of disability progression in patients with RRMS at 2 years follow-up. However, the confidence in this result was graded as moderate by the authors, due to the moderate quality of evidence derived from the trials [35]. Our results are not directly comparable to this network meta-analysis since our aim was not to compare individual DMD against each other. Instead, we systematically evaluated potential sources of heterogeneity in the effect of DMD on disability progression using sensitivity analyses.
Our observation regarding the lack of differential effect in disability progression between "oral" and "injectable" DMD is intriguing. This finding appears to be in line with available data from individual head-to-head comparisons in RCT: (i) TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing—Remitting Multiple Sclerosis) comparing oral fingolimod to intramuscular IFNß-1a [36], (ii) TENERE (the Teriflunomide and Rebif study) comparing oral teriflunomide to subcutaneous IFNß-1a [37] and (iii) CONFIRM [31] (Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis) comparing oral dimethyl fumarate to subcutaneous glatiramer acetate. Interestingly, oral DMD did not reduce disability progression in comparison to the injectable therapies in any of the three trials. Similarly, our finding regarding the lack of differential effect on disability progression between "first" and "second" line DMD is not contradicted by the available data from a single RCT (TRANSFORMS) [36]. Notably, no direct comparisons were performed in the SENTINEL (Safety and Efficacy of Natalizumab in combination with Interferon Beta-1a in patients with Relapsing Remitting Multiple Sclerosis) trial between natalizumab and intramuscular IFNß-1a since the active treatment group was allocated to combination therapy with natalizumab and IFNß-1a [38].

Certain limitations need to be acknowledged in the interpretation of our study results. First, in the current systematic review and meta-analysis we evaluated only the effect of disability worsening, without reporting data on other established markers of disease activity (freedom of...
relapse, lack of new/enlarging T2 lesions and gadolinium-enhancing lesions on magnetic resonance imaging) [39] or brain volume loss [40]. However, in a large multicentre study both brain atrophy and lesion volumes were also found to be significant predictors of long term disability in patients with MS [41]. Likewise, progression in disability (measured with the EDSS scale) was found be directly associated with regional grey matter atrophy in a follow-up MRI evaluation study of patients with RRMS [42]. Furthermore, we have recently reported that DMD for RRMS appear to be effective in attenuating brain atrophy using a similar meta-analytical approach, while DMD benefit on brain volume loss increased linearly with longer treatment duration [11]. Second, four potentially eligible studies were excluded from the final quantitative assessment (meta-analysis) because they provided neither percentages nor numbers of patients with disability progression during the study period [18–21]. As for the included study protocols there is also an unclear risk for selection bias in 2 of them due to non adequate report in random sequence generation and allocation concealment [22, 23]. Third, most of the study protocols reported either considerable (5–20%) [22–27] or significant (>20%) [28–32] rates of loss to follow-up during the study period. Moreover, bias related to funding source is a major concern for all included studies, as they disclose financial and/or other support from the pharmaceutical industries that produce the drug under consideration in each trial. Finally, we should underline that independent studies were compared in the present meta-analysis, and thus all inferences among different DMD should be interpreted with caution.
In conclusion available DMD appear to be effective in reducing the disability progression in patients with RRMS, independent of the route of administration and their classification as “first” or “second” line therapies. However, attrition and funding source biases need to be taken into account in the interpretation of these findings.

Supporting Information
S1 Fig. Funnel plot for the risk of publication bias.
(TIF)

S2 Fig. Meta-regression analysis on the association between the percentage of patients with disability progression and study duration.
(TIF)

S1 PRISMA Checklist. PRISMA 2009 Checklist.
(DOC)

S1 Table. Study designs and baseline characteristics of the eligible studies included in meta-analysis.
(DOC)

Acknowledgments
The authors would like to thank the Hellenic Academy of Neuroimmunology (HELANI) for supporting their research with an unrestricted grant for publication fees.

Author Contributions
Conceived and designed the experiments: GT AHK ED. Performed the experiments: GT AHK. Analyzed the data: GT AHK. Wrote the paper: GT AHK NG GMH IH PP CK KV ED.

References
1. Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014; 2014:262350. doi:10.1155/2014/262350 PMID: 24883205

2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33:1444–52. PMID:6685237

3. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurologic change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011; 17:970–9. doi:10.1177/1352458511399611 PMID: 21421809

4. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013; 40:307–23. PMID: 23603165

5. Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One. 2012; 7:e38661. doi:10.1371/journal.pone.0038661 PMID: 22780406

6. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2012; 25 Suppl:S11–9. PMID: 22398660

7. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2007; 69:1498–507. PMID: 17699802

8. Izquierdo, García-Agua Soler N, Rus M, García-Ruiz AJ. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Brain Behav. 2015; 5:e00337. doi:10.1002/brb3.337 PMID: 26085963
9. Kappos L, Kuhle J, Multanen J, Kremenchutsky M, Verdun di Cantogno E, Corneliße P, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry. 2015 Sep 15. doi: 10.1136/jnnp-2014-310024 [Epub ahead of print]

10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 2009; 62:e1–34

11. Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Kiliäreas C, et al. The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One. 2015; 10:e0116511. doi: 10.1371/journal.pone.0116511 PMID: 25756363

12. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928 doi: 10.1136/bmj.d5928 PMID: 22008217

13. Sacket D L, Richardson W S, Rosenberg W. Evidence-Based Medicine: How to Practice and Teach EBM.

14. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013 Dec 20; 12:ED000075. PMID: 24575439

15. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions website. http://handbook.cochrane.org/chapter_9/9_9 analysing_data_and_undertaking_meta_analyses.htm. Updated March 2011. Accessed February 4th, 2014.

16. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011; 343:d4002. doi: 10.1136/bmj.d4002 PMID: 21784880

17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–634 PMID: 9310563

18. Comi G, Filippi M, Wolinsky JS, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001; 49:399–7. PMID: 11261502

19. De Stefano N, Curtis F, Stubinski B, Blevins G, Drulovic J, Issard D, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Mult Scler. 2010; 16:888–92. doi: 10.1177/1352458510362442 PMID: 20200197

20. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009; 15:219–28. doi: 10.1177/1352458508097299 PMID: 18755819

21. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001; 124:1803–12. PMID: 11522582

22. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. J. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993; 43:655–61. PMID: 8469318

23. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995; 45:1268–76. PMID: 7617181

24. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39:285–94. PMID: 8602746

25. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998; 352:1498–504. PMID: 9820297

26. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899–910. PMID: 16510744

27. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362:387–401. doi: 10.1056/NEJMoa0909949 PMID: 20089952
28. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13:545–56. doi: 10.1016/S1474-4422(14)70049-3 PMID: 24685276

29. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365:1293–303. doi: 10.1056/NEJMoa1014656 PMID: 21991951

30. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2012; 13:247–56. doi: 10.1016/S1474-4422(12)70308-9 PMID: 24461574

31. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012; 367:1087–97. PMID: 22992072

32. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selimaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367:1098–107. PMID: 22992073

33. Khan O, Rieckmann P, Boyko A, Selimaj K, Zivadinov R; GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013; 73:705–13. doi: 10.1002/ana.23936 PMID: 23686621

34. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014; 13:657–65. doi: 10.1016/S1474-4422(14)70068-7 PMID: 24794721

35. Filippini G, Del Giovane C, Vacchi L, D’Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013; 6:CD008933. doi: 10.1002/14651858.CD008933.pub2 PMID: 23744561

36. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362:402–15. doi: 10.1056/NEJMoia0907839 PMID: 20689954

37. Vermersch P, Czonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scier. 2014; 20:705–16. doi: 10.1117/1352458513507821 PMID: 24126064

38. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354:911–23. PMID: 16510745

39. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010; 74 Suppl 3:S3–7. doi: 10.1212/01.wnl.0b013e3181db651c PMID: 20421571

40. Kappos L, Radue E, Freedman M. Inclusion of brain volume loss in a revised measure of multiple sclerosis disease-activity freedom: the effect of fingolimod. Mult Scier J. 2014; 20:Abstract 1570.

41. Popescu V, Agosta F, Hulst HE, Stuiver IC, Knol DL, Sormani MP, et al. Brain atrophy and lesion load predict long-term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84:1082–91. doi: 10.1136/jnnp-2012-304094 PMID: 23524331

42. Hofstetter L, Naegelin Y, Filli L, Kuster P, Traud S, Smieskova R, et al. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. Mult Scier. 2014; 20:202–13. doi: 10.1117/1352458513493034 PMID: 23804554